Glycotargeting Therapeutics for Liver-Mediated Immune Tolerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing approaches for targeting antigens to erythrocytes for tolerization have limitations, and there is a need for alternative methods to effectively treat transplant rejection, autoimmune diseases, and immune responses against therapeutic agents.
Innovation Solution
Development of compositions comprising a compound of Formula 1, which includes an antigen or its tolerogenic portion, a linker moiety, and a liver-targeting moiety, specifically galactose or galactosamine conjugated at C1, C2, or C6, to target hepatocytes, LSECs, and Kupffer cells, facilitating tolerization and clearance of unwanted immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigens are targeted to erythrocytes for tolerization, then immune response is reduced, but the approach has limitations and alternative methods are needed
Solution Approach 1:
The patent introduces liver cells (hepatocytes, LSECs, Kupffer cells) as intermediary cells to mediate antigen presentation and tolerization. The compositions utilize asialoglycoprotein receptors on these liver cells to internalize and process antigens, thereby inducing tolerance. This intermediary approach overcomes the limitations of erythrocyte targeting by providing a more versatile and reliable system for achieving immune tolerance through liver-based antigen presentation.
2Productivity
If liver-targeting moieties are used to target hepatocytes, then clearance of unwanted immune responses is improved, but the complexity of composition formulation increases
Solution Approach 1:
The patent employs galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetylglucosamine as liver-targeting moieties that conjugate to the antigen at specific positions (C1, C2, or C6). By modifying the glycosylation parameters of the antigen composition, the patent achieves selective targeting to asialoglycoprotein receptors on liver cells. This parameter-based targeting strategy enables rapid clearance of unwanted immune responses while maintaining manageable formulation complexity through standardized conjugation methods.
3Measurement precision
If galactose or galactosamine are conjugated at C1, C2, or C6, then liver targeting specificity is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent applies local quality modification by conjugating galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetylglucosamine at specific positions (C1, C2, or C6) of the antigen molecule. This localized glycosylation creates specific recognition sites on the antigen that bind to asialoglycoprotein receptors on liver cells. The local quality approach enhances liver targeting specificity while the patent provides flexibility in conjugation position options to manage manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce unwanted immune responses by at least 50% within 12 to 48 hours by targeting liver cells, thereby reducing transplant rejection, autoimmune disease, and allergic responses.
Implementation Method 1
targeting liver cells, thereby reducing transplant rejection, autoimmune disease, and allergic responses
Data Source
AI summary
Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.